Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE | P16581 | 19/20 | 0.72 |
| ▸ | FGF1 | P05230 | 1/20 | 0.30 |
| ▸ | FGF2 | P09038 | 1/20 | 0.30 |
| ▸ | VEGFA | P15692 | 1/20 | 0.30 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22247293 | 0.95 | SELE (0.68) | SELE | |
| SCHEMBL22247261 | 0.95 | SELE (0.72) | SELE | |
| SCHEMBL22247270 | 0.93 | SELE (0.66) | SELE | |
| SCHEMBL22247257 | 0.93 | SELE (0.65) | SELE | |
| SCHEMBL22247381 | 0.92 | SELE (0.61) | SELEFGF1FGF2VEGFAHPSE | |
| SCHEMBL24621682 | 0.92 | SELE (0.61) | SELE | |
| SCHEMBL22247248 | 0.91 | SELE (0.68) | SELE | |
| SCHEMBL24621684 | 0.89 | SELE (0.81) | SELE | |
| SCHEMBL24621727 | 0.87 | SELE (0.85) | SELE | |
| SCHEMBL24621728 | 0.87 | SELE (0.85) | SELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220220144-A1 | MULTIMERIC PAN-SELECTIN ANTAGONISTS | GLYCOMIMETICS, INC. (US) | 2022-07-14 | — | — | US | disclosed |
| WO-2020150263-A1 | SELECTIN OR GALECTIN ANTAGONISTS FOR TREATING CYTOKINE RELEASE SYNDROME AND CRS-INDUCED NEUROTOXICITY | MAGNANI JOHN L (US) | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220144-A1 | MULTIMERIC PAN-SELECTIN ANTAGONISTS | SELE, SELP, BSG | SELE 1/4885FGF1 2674/4885FGF2 2454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.